LMNX - Luminex receives BARDA funding

Luminex (LMNX) trades 1.5% higher after receiving $11.3M in funding from the Biomedical Advanced Research and Development Authority ((BARDA)).These funds will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus targets with the SARS-CoV-2 target that can be run on all ARIES Systems. This will allow laboratories to run one test instead of two or more without sacrificing clinical results."We believe that this targeted multiplex assay will play a pivotal role in helping healthcare professionals efficiently and effectively manage individuals with respiratory illness symptoms for years to come," Chairman, President and CEO Nachum "Homi" Shamir commented.

For further details see:

Luminex receives BARDA funding